OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
12
Results
Show all
Save search
Copy query
Show results for
Unknown
(12)
Publication Date
Release Date
2019
(4)
2016
(2)
2023
(1)
2022
(1)
2021
(1)
2018
(1)
2017
(1)
2012
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes.
Not available
S-EPMC6588019
|
biostudies-literature
Cite
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.
Not available
S-EPMC4862980
|
biostudies-literature
Cite
Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
Not available
S-EPMC6618272
|
biostudies-literature
Cite
The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.
Not available
S-EPMC6099439
|
biostudies-literature
Cite
Nurse-Moderated Internet-Based Support for New Mothers: Non-Inferiority, Randomized Controlled Trial.
Not available
S-EPMC5547246
|
biostudies-literature
Cite
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Not available
S-EPMC10731422
|
biostudies-literature
Cite
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.
Not available
S-EPMC6349278
|
biostudies-literature
Cite
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.
Not available
S-EPMC6911166
|
biostudies-literature
Cite
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Not available
S-EPMC10502468
|
biostudies-literature
Cite
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Not available
S-EPMC10792546
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets